SPECIAL REPORT

Over the past 15 years, most MS treatment trials have used an active control, which has generated substantial data with which to compare the efficacy and safety of starting treatment with a higher-efficacy versus lower-efficacy disease-modifying therapy (DMT). Read More

Modelling MS Endowment
Move over EAE – researchers have introduced a new wrinkle to MS animal models. Seems that MS is remarkably similar to the necrotizing meningoencephalitis (NME) that affects Pug dogs (Windsor et al. Am J Vet Res 2023; epublished November 6, 2023). The condition is also known as Pug Dog encephalitis. As with MS, genetic factors and autoimmunity contribute to the etiology of NME. The early clinical courses are similar although the main pathological feature of NME is necrosis rather than demyelination. Interestingly, an earlier genome-wide association study of NME identified genes of interest, including DRB1 and DQA1, both of which play a role in MS (Greer et al. Tissue Antigens 2010;76:110-118). Read More

The year 2023 was marked by a number of anniversaries and what may be a turning point in the approach to MS research and clinical practice. Read More